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ABSTRACT 
Diabetes doubles the risk of bone fracture. Poor quality of bone in 
diabetes is largely linked to diminished bone formation and bone organic phase 
abnormalities. Studies indicated that in diabetes, glycation of type I collagen, the 
most abundant protein in bone extracellular matrix, prompts abnormal 
arrangement of collagen molecules leading to weak bones. In addition, diabetic 
bone fragility is attributed to reduced levels of lysyl oxidase enzyme-dependent 
collagen cross-links. However, the mechanism underlying the presence of lower 
levels of enzymatic collagen cross-links in diabetic bone has not been directly 
investigated. Thus, we investigated the regulation of lysyl oxidase in bone under 
diabetic conditions. Our in-vitro model examined collagen and glycated-collagen 
regulation of lysyl oxidase in primary rodent osteoblasts. Our findings indicate 
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that collagen up-regulates lysyl oxidase in osteoblasts, while glycated-collagen 
fails to regulate lysyl oxidase. To determine the mechanism of collagen up-
regulation of lysyl oxidase, we studied two classes of collagen receptors: 
Discoidin Domain-Receptor 2 (DDR2) and integrins. Inhibitor and knockdown 
studies indicated that collagen up-regulates lysyl oxidase through DDR2. 
Furthermore, glycated-collagen-DDR2 binding and activation analyses showed 
that collagen glycation disrupted collagen-DDR2 binding and activation, pointing 
to a mechanism for the diminished levels of lysyl oxidase and consequent low 
lysyl oxidase-derived cross-links in diabetic bone. Our in-vivo studies focused on 
lysyl oxidase regulation in mouse calvarial bone healing tissues under diabetic 
conditions. These experiments revealed that diabetes up-regulates lysyl oxidase 
mRNA and enzyme activity in partially healed bone (day 7). We next performed 
histological analyses on day 7 healing bone. Data suggest that hematomas, 
which form in the initial stage of bone healing, do not resolve in diabetic mice. 
Unresolved hematomas are rich in growth factors, which could explain elevated 
levels of lysyl oxidase in diabetic healing bone. Taken together, this study 
provides a novel mechanism by which collagen glycation disrupts the regulation 
of lysyl oxidase in diabetic bone fragility. Additionally, we found that the excess 
formation of non-mineralized fibrotic matrix might be one of the mechanisms 
behind impaired intramembranous bone healing in diabetes. 
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1. Introduction 
1.1. Diabetes 
Diabetes mellitus is a group of metabolic diseases that share elevated 
levels of blood glucose, a symptom that is often referred to as hyperglycemia. 
Diabetes mellitus is broadly classified into type 1 and type 2 diabetes, largely 
based on the mechanisms leading to hyperglycemia. An individual shifts from 
normal glucose tolerance to impaired glucose tolerance prior to the onset of 
diabetes (Longo, 2012). In type 1 diabetes, the destruction of pancreatic ~-cells­
often due to an abnormal autoimmune response - results in reduced production 
of insulin (insulin deficiency) and consequently induction of hyperglycemia. In 
type 2 diabetes, however, hyperglycemia is a byproduct of decreased cellular 
consumption of glucose, impaired secretion of insulin and increased glucose 
production, all at various degrees (Longo, 2012). 
The worldwide prevalence of diabetes has drastically increased from 30 
million cases in 1985 to 285 million (9.5-fold) in 2010 (Shaw eta/., 2010) with an 
estimate of about 15 diabetic cases per 1000 of individuals in the United States 
(21% of the population) in 2050 (Boyle eta/., 2010). The Center for Disease 
Control and Prevention (CDC) reported that 25.8 million Americans had diabetes 
(8.3% of the population) in 2010 (CDC, 2011 ). 
1 
1.2. Chronic Complications of Diabetes 
Diabetes causes an extensive list of complications in nearly every tissue. 
Chronic complications of diabetes commonly arise from hyperglycemia and can 
be divided into vascular and non-vascular complications. Examples of vascular 
complications are retinopathy, neuropathy, nephropathy, and coronary heart 
disease. Non-vascular complications are infections, diabetic foot, skin changes 
and bone fragility (Cecil et al., 2008). Diabetes also induces oral complications, 
which are characterized by both vascular and non-vascular abnormalities in 
mineralized and non-mineralized tissues (Ship, 2003). For example, diabetes 
exacerbates the inflammatory response to periodontal pathogens, increasing the 
severity of complications associated with destructive periodontal disease such as 
alveolar bone loss (Liu eta/., 2006). 
1.3. Pathobiology of Diabetic Complications 
Five potential mechanisms have been proposed to explain hyperglycemia-
induced tissue damages, which bring about diabetes-associated complications 
(Brownlee, 2005). 
1.3.1. Polyol Pathway 
The polyol pathway (sorbitol pathway) metabolizes glucose to fructose via 
an intermediate product: sorbitol (Hers, 1956). The first report on the role of the 
polyol pathway in diabetic complications was in 1959, which showed the elevated 
levels of polyols in diabetic rats lenses (Van Heyningen, 1959). Later Gabbay et 
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a/. showed similar accumulations of polyols in peripheral nerves and spinal cord 
of diabetic rats (Gab bay et a/., 1966). Studies since 1966 concluded that the 
fluxes of the polyol pathway in diabetes depletes NADPH in cells, which is 
required for a protective cellular mechanism against reactive oxygen species, 
thereby damages the cells (Kinoshita, 1990). 
1.3.2. Advanced Glycation End Products 
The second mechanism is the formation and accumulation of advanced 
glycation end products (AGEs) in diabetes. Elevated levels of glucose and its 
metabolites in diabetes prompt non-enzymatic modifications of proteins. 
Specifically, aldehyde or ketone groups of carbohydates or oxidized lipids react 
with the amine group of a lysine, hydroxylysine or arginine side chain of proteins 
to ultimately form non-enzymatic modifications some of which are cross-links. 
The heterogeneous products of these modifications are collectively called AGEs. 
Carboxymethyl lysine (CML) modification of proteins, which is formed by 
the oxidative degradation of a glycated lysine residue, is a simple form of protein 
glycation (Figure 1) (Ahmed et a/., 1986). High levels of CML modified proteins 
have been reported in diabetic patients (Schleicher eta/., 1997). CML modified 
proteins are also known to bind to the Receptor of AGE (RAGE) and activate 
AGE-RAGE signaling, which has been linked to many diabetes-associated 
complications (Kislinger eta/., 1999). 
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AGE modifications were initially discovered in hemoglobin (Bunn et a/., 
1978; Koenig et a/., 1976). AGE modifications can damage tissues through three 
mechanisms. 
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Figure 1. Carboxymethyl Lysine Modification 
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Figure 1. Carboxymethyl Lysine Modification 
The reaction scheme represents the glucose modification of a lysine 
residue to form carboxymethyl lysine. This modification on a protein, such as 
collagen, results in the generation of a simple form of advanced glycation end 
products, which have been detected in diabetic patients. 
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(i) The AGE modification of intracellular proteins interfere with cellular 
physiological functions of these proteins (Giardino et al., 1994). (ii) The glycation 
of extracellular matrix components can disrupt the structure and characteristics of 
these ECM components (Paul et al., 1996). (iii) AGEs bind to various AGEs-
specific receptors and induce pathological signaling pathways, which have 
shown to be linked to diabetic complications (VIassara, 2001; Yan eta/., 201 0). 
1.3.3. Protein Kinase C 
Activation of protein kinase C (PKC) is the third mechanism for diabetic 
complications. Hyperglycemia up-regulates the production of diacylglycerol, 
which is a cofactor for PKC activation. Numerous cytokines and growth factors 
are regulated by PKC that are linked to diabetic complications. For example, 
PKC up-regulates Transforming Growth Factor P (TGF- P) that enhances 
biosynthesis and accumulation of collagen, which has been contributed to the 
capillary occlusion in diabetic nephropathy (Koya eta/., 1997). 
1.3.4. Hexosamine Pathway 
Intracellular glucose is mainly metabolized through glycolysis in which 
glucose is converted to glucose-6 phosphate and then fructose-6 phosphate 
follows the glycolytic pathway. The hexosamine pathway is a side pathway to 
glycolytic pathway where frucotose-6 phosphate converts to UDP (uridine 
diphosphate) N-acetylglucosamine, a donor for 0-GicNAc modifications. The 
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over activation of the hexosamine pathway in diabetes up-regulates the 
production of UDP- N-acetylglucosamine mediating 0-GicNAc modifications of 
transcription factor and stimulates pathological gene expressions (Wells et a/., 
2003). For example, 0-GicNAc modifications of Specificity Protein 1 (SP1) 
transcription factors under high glucose conditions up-regulates the production of 
TGF-~ and plasminogen activator inhibitor-1 (PAI-1), which could contribute to 
diabetic complication as stated above (Du eta/., 2000). 
1.3.5. Reactive Oxygen Species 
Michael Brownlee and co-workers proposed a unifying mechanism in 
which hyperglycemia-induced over production of reactive oxygen species (ROS) 
is the common up-stream link among all other four mechanisms of diabetic-
associated pathologies (Brownlee, 2005). Specifically, ROS inhibits 
glyceraldehyde-3 phosphate dehydrogenase (GAPDH), a key glycolytic enzyme, 
which stimulates the polyol , PKC, and Hexoseamine pathways (Duet a/., 2003). 
1.4. Bone Complications in Diabetes 
As noted earlier, hyperglycemia is a common factor in both forms of 
diabetes, which induces diabetes-associated complications including bone 
abnormalities. Both types of diabetes doubles the risk of bone fracture (Bouillon, 
1991). Bone complications in diabetes were initially reported in Type 1 diabetes 
in children. In 1927, Morrison and Bogan discovered that bone development is 
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delayed in children with type 1 diabetes (Morrison et a/., 1927). Since then 
numerous human and animal studies have shown the weak-bone phenotype in 
type 1 diabetes (reviewed in Bouillon, 1991). Additionally, recent evidence from 
studies on bone complications in type 2 diabetes indicates a high risk of bone 
fracture in cases with type 2 diabetes (Giangregorio et a/., 2012; Kanis et a/., 
2008; Leslie eta/., 2012). 
The pathogenesis of weak bones in diabetes, also refereed as diabetic 
osteopenia, can be broadly divided into cellular and extracellular (ECM) 
pathologies. 
1.5. Pathology of Diabetic Bone Complications 
1.5.1. Cellular Complications 
Diabetes leads to three essential cellular complications in bone. (i) 
Diabetes diminishes the differentiation of bone-forming cells (osteoblasts) 
(Verhaeghe et a/., 1990) and it also induces apoptosis (Aiikhani et a/., 2007) in 
these cells. (ii) In diabetes, mesenchymal stromal cells, the origin of osteoblast 
cells in bone, differentiate to the adipogenic lineage instead of the osteogenic 
lineage (Botolin et a/., 2005). (iii) The role of osteoclasts in diabetic bone 
disorders is not clear. Diabetes may primarily reduce or not change the formation 
of osteoclasts (bone-resorbing cells). He et. a/. reported on reduced 
osteoclastogenesis in an experimental periodontitis model under diabetic 
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conditions (He et a/., 2004). Recent evidence suggests that although bone 
marrow-derived osteoclast differentiation is diminished in diabetic mice, the 
diabetic osteoclasts are hyperactive (Catalfamo et a/., 2013). Further studies, 
perhaps on human subjects, should clarify the hyper-responsiveness of 
osteoclasts in diabetes. 
Together, these complications in diabetes down-regulate bone formation 
and promote bone fragility. 
1.5.2. Extracellular Complications 
In addition to its cellular effects, diabetes modifies bone organic matrix. 
Bone strength is determined by bone mineral density (BMD) and the structure of 
the bone organic phase (Davison et a/., 2006). BMD is reduced in type 1 
diabetes (T1 D) by approximately 10% (Bouillon, 1991; Neumann eta/. , 2011 ). A 
meta-analysis on 80 epidemiological studies from 1945 to 2005 also reported on 
reduced levels of BMD in type 1 diabetes and increased levels of BMD in type 2 
diabetes (T2D) yet the risk of bone fracture was higher for both types of diabetes. 
(Vestergaard, 2007). Additionally, a recent report from the Rotterdam study of 
4,135 Dutch men and women suggested higher BMD levels in type 2 diabetic 
individuals compared to non-diabetic individuals, and BMD levels in inadequately 
controlled diabetic subjects was further increased compared to adequately 
controlled diabetic individuals (Oei eta/., 2013). 
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Taken together, evidence indicating higher BMD in T2D and lower BMD in 
T1 D despite the fact that the risk of bone fracture is higher in both forms of 
diabetes suggest that diabetic bone abnormalities are more likely linked to bone 
organic matrix complications and not BMD (Merlotti eta/., 201 0). 
Type I collagen is the most abundant protein in bone organic matrix and it 
determines bone strength along with bone mineral density (Boskey et a/., 1999). 
Collagen is synthesized and secreted by osteoblasts. Collagen undergoes post-
translational modifications and assembles to form collagen fibrils in the 
extracellular matrix (Figure 2). 
1.5.2.1. Lysyl Oxidase 
To stabilize collagen fibrils, an enzyme called lysyl oxidase catalyzes 
oxidative deamination of peptidyl-lysine and hydroxylysine (HL) residues in 
collagen to form peptidyl aldehydes. Lysine or HL aldehydes spontaneously react 
with amine groups of lysine or HL residues in the same region of the molecule to 
form intermolecular cross-links between collagen molecules. Figure 3 shows the 
stoichiometry of the lysyl oxidase catalyzed reaction followed by the formation of 
dehydrolysinonorleucine (deLNL), which is one of a variety of normal biosynthetic 
collagen cross-links. Lysyl oxidase inhibition results in a weak-bone and joint 
phenotype called osteolathyrism (Selye, 1957). 
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Figure 2. Collagen Biosynthesis and Post-Translational Modification 
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Figure 2. Collagen Biosynthesis and Post-Translational Modification 
Collagen is synthesized and secreted by osteoblasts. It then undergoes 
post-translational modifications and assembles to form collagen fibrils in ECM. 
To stabilize collagen fibrils, an enzyme called lysyl oxidase oxidatively 
deaminates the side chain amino group of lysine or hydroxylysine (HL) residues 
in the telopeptide region of collagen molecules. Lysine or HL aldehydes then 
spontaneously react with amine groups of lysine or HL residues in the same 
region of the molecule to form intermolecular and intramolecular cross-links 
(Figure 2; red marks) between collagen molecules. Lysyl oxidase inhibition 
results in a weak bone and joint phenotype called osteolathyrism. 
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Figure 3. Stoichiometry of Lysyl Oxidase-Catalyzed Reaction and Formation of 
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Figure 3. Stoichiometry of Lysyl Oxidase-Catalyzed Reaction and Formation of 
deLNL 
The presented stoichiometry shows the stoichiometry of the lysyl oxidase 
catalyzed reaction followed by the formation of dehydrolysinonorleucine (deLNL), 
which is one of a variety of normal biosynthetic collagen cross-links. 
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In diabetes, elevated levels of glucose and/or its metabolites result in non-
enzymatic modifications of extra- and intra-cellular proteins and lipids. 
Specifically, in proteins, aldehyde or ketone groups of carbohydates or oxidized 
lipids react with the amine group of a lysine, hydroxylysine or arginine side chain 
to ultimately form non-enzymatic cross-links (Monnier et a/., 2005). The 
heterogeneous products of these modifications are collectively called advanced 
glycation end products (AGEs). 
Collagen is the most abundant protein in bone organic matrix. It is known 
that non-enzymatic cross-linking of AGE moieties to collagen molecules 
interferes with normal arrangement of collagen fibrils thereby lessens bone 
strength in diabetes (Paul et a/., 1996). Saito et. al. reported that diabetic bone 
has lower enzymatic (lysyl oxidase-dependent) collagen cross-links compared to 
non-diabetic bone in a rat model (Saito eta/., 2006). Bone lysyl oxidase levels 
were not measured in this study. 
1.5.3. Current Knowledge on the Pathogenesis of Diabetic Osteopenia 
Impaired bone formation because of bone cellular abnormalities partly 
explained fragile bones in diabetes. In addition, bone matrix modifications have 
been linked to weak bones in diabetes. Bone matrix abnormalities in diabetes 
can origin from (a) accumulated non-enzymatic AGE-collagen cross-links in the 
matrix and/or (b) reduction of enzymatic collagen cross-links. Numerous studies 
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supported the former hypothesis, yet the role of reduced lysyl oxidase-dependent 
collagen cross-links in diabetic weak bones remains unknown. 
1.6. Lysyl oxidase Regulation in the Non-bone Tissues in Diabetes 
The regulation of lysyl oxidase under diabetic conditions was examined in 
non-bone tissues such as retina, lung, and skin. 
Rat retinal endothelial cells under high glucose (30 mmol/1) for 7 days showed 
elevated levels of lysyl oxidase protein and enzyme activity, which increased the 
permeability of endothelial cell monolayers. The authors suggested that high-
glucose-induced lysyl oxidase contributes to thickening of vascular basement 
membranes in diabetes, which eventually leads to diabetic retinopathy 
(Chronopoulos et a/., 201 0). The Kagan group reported on the 2-3 fold up-
regulation of lysyl oxidase activity in lung tissue of chemically induced diabetic 
rats (Madia eta/., 1979). In addition, lysyl oxidase activity was shown to increase 
in the skin of chemically induced diabetic rats (Ramamurthy et a/., 1983). 
Moreover, Buckingham and Reiser reported on up-regulated lysyl oxidase 
enzyme-dependent cross-links in the skin of diabetic human subject although 
lysyl oxidase protein levels or enzyme activity was not measured in this study 
(Buckingham eta/., 1990). 
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1.7. Oral Complications in Diabetes 
Oral health complications in diabetes include oral candidiasis, salivary 
dysfunction (xerostomia), oral mucosal disease, and higher risk and severity of 
periodontal diseases and dental caries (Mealey et a/., 2007; Ship, 2003). The 
chronic inflammation in diabetes is responsible in the onset of periodontal 
diseases, salivary dysfunction, and oral infections linked to diabetes (Lamster et 
a/., 2008). The mechanism of increased dental caries in diabetes compare to 
non-diabetic individuals is unclear (Garton eta/., 2012). 
Diabetes-induced periodontal diseases and dental caries mainly result in 
tooth loss, which is often replaced with dental implants. Compelling evidence 
suggests that the integration of dental implants into the surrounding bone tissue 
is less in diabetic patients. Since the survival of dental implants is determined by 
its bone integration, diabetes increases the risk of dental implant failure 
(Marchand et a/., 2012). Dental implant failure in diabetic patients is highly 
correlated with uncontrolled hyperglycemia (Marchand eta/., 2012). Poor quality 
of bone and diminished bone formation as discussed above might explain the 
lower success rate of dental implant treatment in diabetic patients. Further 
understating of bone complications in diabetes could provide knowledge to 
improve implant dentistry for these medically compromised patients. 
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2. Objective 
Diabetes doubles the risk of bone fracture. Bone strength is determined by 
bone mineral density and the structure of bone organic extracellular matrix. 
Evidence from human and animal studies suggests that diabetic bone fragility is 
largely linked to the abnormalities in the bone organic phase (Bouillon, 1991 ). 
Collagen is the most abundant protein in bone organic extracellular matrix, which 
is synthesized and secreted by bone-forming cells (osteoblasts) and then 
undergoes post-translational modifications in the extracellular matrix (see section 
1.5.2.1 ). Collagen molecules in the extracellular matrix assemble to form fibrillar 
collagen. Lysyl oxidase is an enzyme required to catalyze the formation of 
collagen cross-links to stabilize fibrillar collagen. Lysyl oxidase has a pivotal role 
in bone formation and remodeling. Inhibition of lysyl oxidase prompts bone 
abnormalities called osteolathyrism (Selye, 1957). 
Studies in diabetic rats indicate that the levels of lysyl oxidase enzyme-
dependent collagen cross-links are reduced in diabetic bones. The reduction of 
these cross-links could explain weak-bones in diabetes although the mechanism 
of reduced collagen cross-links is unknown. Therefore, we sought to study the 
regulation of lysyl oxidase under diabetic conditions. 
To this end, a series of in-vitro and in-vivo experiments were carried out 
using two models: (i) primary rodent osteoblasts and (ii) calvarial bone healing in 
diabetic mice. The first objective was to investigate the regulation of lysyl oxidase 
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by carboxymethyl lysine collagen, a simple form of AGEs triggering many 
diabetes-associated complications, in primary osteoblasts. We hypothesized that 
glycated collagen down-regulates lysyl oxidase through AGE/RAGE axis. The 
second objective was to assess the regulation of lysyl oxidase in calvarial bone 
healing tissue under diabetic conditions. We used a bone healing model since 
osteoblasts are highly functional during the healing process. 
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3. Materials and Methods 
3.1. In-Vitro Experiments 
3.1.1. Isolation of Rat and Mouse Primary Calvarial Osteoblasts 
3.1.1.1. Mouse Primary Calvarial Osteoblasts 
Postnatal (1-3 day old) BALB/cByJ mice (Jackson Laboratory) were 
euthanized, and the calvaria, excluding the occipital bone, were surgically 
dissected. The Boston University Institutional Animal Care and Use Committee 
(IACUC) approved all animal protocols. Harvested bones were sequentially 
digested for three cycles (20, 20, and 90 minutes) using 15 ml of a collagen-
trypsin cocktail (0.1% collagenase P and 7.5% of 2.5% trypsin) in PBS, with the 
third digest being enriched for osteoblasts as originally described (Bellows et a/., 
1986) and previously carried out in our laboratory (Vora eta/., 2010). For each 
digestion cycle, suspended bone tissues were incubated at 3r C with gentle 
horizontal rotation. Bone tissues were washed with PBS and re-suspended in 
fresh cocktail between each cycle. After the final 90 minute digestion, the mixture 
containing residual bones was centrifuged at 700 x g for 10 minutes at 4 o C. The 
supernatant liquid and residual bones were carefully discarded, and the cell 
pellet containing primary osteoblasts was re-suspended in the growth medium. 
Isolated primary cells were counted and seeded at 2 x 106 cells per 1 00 mm 
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diameter culture dish. After 3 or 4 days, cells were passaged and plated 
accordingly for each experiment as described in Results. 
3.1.1.2. Rat Primary Calvarial Osteoblasts 
CD®IGS 001 rats (Charles River Laboratory) were used to isolate rat 
osteoblasts. The calvaria of 16-18 day old embryonic rats were dissected using a 
pair of miniature scissors. Rat primary osteoblasts were isolated following the 
same protocol as mouse cells, except that rat cells were seeded at 5 x 1 05 cells 
per 100 mm diameter culture dish. 
3.1.2. Cell Culture 
Rat and mouse primary osteoblasts were each respectively grown in the 
growth medium (a-MEM medium supplemented with 0.1 mM nonessential amino 
acids, 10% fetal bovine serum, and 100 Units/ml Penicillin and 0.1 mg/ml 
Streptomycin) at 3r C and 5% C02 in a fully humidified incubator. For 
experiments with non-differentiated osteoblasts, cells were grown to 80% visual 
confluence. The medium was then replaced with the serum-free medium 
containing 0.1% bovine serum albumin for a minimum of 12 hours. Cells were 
then treated with either experimental or control medium. 
To induce differentiation, the growth medium was replaced with the 
differentiation medium [growth medium containing freshly prepared ascorbic acid 
(50 tJg/ml), J3-glycerophosphate (10 mM), and dexamethasone (10 nM)] at 100% 
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visual confluence. During the course of differentiation the media were refreshed 
every second day. Experiments with differentiated rat and mouse osteoblasts 
were conducted on 7 -day differentiated cells since our laboratory previously 
showed that day 7 differentiated osteoblasts initiate to increase the expression of 
lysyl oxidase while type I collagen expression levels is at its maximum levels 
during the course of differentiation in these cells (Hong eta/., 2004). 
3.1.3. Preparation of Glycated Type I Collagen and Glycated Bovine Serum 
Albumin 
3.1.3.1. Type I Collagen 
Acid soluble calf skin type I collagen (Sigma cat#3515) was chemically 
modified to generate N-E-(carboxymethyl)-lysine-collagen (CML-collagen) and 
control collagen as previously described (Aiikhani et a/., 2007; Kislinger et a/., 
1999). Specifically, collagen was dissolved in 1 mM HCI, and was then divided 
into two batches: Non-glycated control-collagen, and CML-collagen, respectively. 
To prepare CML-collagen, dissolved collagen was incubated overnight at 3r C 
with 0.45 M sodium cyanoborohydride and 155 mM sodium glyoxylate in 0.2 M 
sodium phosphate buffer pH 7.8. Note that dissolved collagen was diluted with 
sodium phosphate buffer first and then the pH was adjusted to 7.8. Next, sodium 
cyanoborohydride was added to dissolved collagen in sodium phosphate buffer 
at pH 7.8. Finally sodium glyoxylate was added, and the mixture was incubated 
overnight. The control-collagen batch was incubated identically but without 
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glyoxylic acid, thereby making CML-modification impossible. Control- and CML-
collagen were then dialyzed against fresh deionized water three times for 12 
hours each time at 4° C. Successful modification of collagen was indicated by 
slower mobility of CML-collagen on SDS-PAGE gels and by its high 
immunoreactivity with anti-CML antibody (R&D system cat#3247) compared to 
control-collagen (Figure 4; Results section). The supernatant of centrifuged CML-
collagen was used in all the experiments since a small fraction of CML modified 
insoluble collagen precipitate (Reiser eta/., 1991), which was excluded to avoid 
its potential non-specific effects on cells. 
A third batch was also prepared, which was labeled vehicle. To prepare 
the vehicle batch, we followed a similar protocol that we use to make CML-
collagen except collagen was not added. The vehicle batch designed such that it 
contains all the reagents, which undergo the chemical modification process, and 
serves as a control group. Basically, to prepare the vehicle batch half of the total 
volume of HCL that used to dissolve type I collagen to make CML-collagen and 
collagen was prepared. Next, the vehicle patch was processed similar to CML-
collagen batch. Vehicle was dialyzed against fresh deionized water three times 
for 12 hours each time at 4° C. 
Aliquots (2 ml) of all three control-collagen, CML-collagen, and vehicle 
were lyophilized and stored at -20° C. One mM HCL (1 ml) was used to dissolve 
the lyophilized control-collagen, CML-collagen, and vehicle the day before the 
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experiment. The concentration of control- and CML-collagen were measured by 
BCA assay. 
3.1.3.2. Bovine Serum Albumin (BSA) 
Fraction V bovine serum albumin (BSA) (EMD Biosciences cat#126609) 
was subjected to the same CML modification protocol (see section 3.1.3.1) and 
CML modification was confirmed with slow mobility and immunoreactivity to the 
anti-CML antibody (Figure 8; Results section). Additionally, the degree of CML 
modifications was quantitated by a colorimetric assay (Trinitrobenzene sulfonate 
assay, TNBS) measuring loss of amino groups (Habeeb, 1966). Specifically, five 
concentrations of BSA or CML-BSA ranging between 0-1 mg/ml were prepared 
by adding soluble proteins to a pre-mixed of 4% NaHC03 (250 JJI) at pH 8.5 and 
0.1% (WIV) TNBS (250 JJL) in dark 1.5 ml micro tubes. The tubes then were 
incubated at 40°C for 2 hours. Next, 125 J..IL of 1 N HCI and 250 J..IL of 10% 
sodium dodecyl sulfate (SDS) were added to each tube. The absorbance for 
each sample was measured at 360 nm using a Berthold TriStar LB 941 plate 
reader. Our analysis suggested the modification of 23% of lysine residues 
(Figure 9; Results section). This value is in the range of physiologic levels of 
lysine loss seen in aging and diabetes for long-lived proteins (Verzijl et al., 2000). 
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3.1.3.3. Cell Treatment with Glycated Collagen or BSA 
Osteoblasts were serum-depleted using the serum-free growth medium 
supplemented with 0.1% BSA for 18 hours. Cells were then treated with 0.2 
mg/ml of control-collagen, CML-collagen (supernatant of spun down CML-
collagen; Figure 4), BSA, CML-BSA or vehicle. CML-collagen modification 
reduces the solubility of collagen and results in precipitation of collagen (Reiser, 
1991). To avoid potential effects of precipitated collagen on cells, we only used 
the supernatant soluble CML-collagen after centrifugation of CML-collagen for 10 
minutes at 10,000 X g. CML-modifications of supernatant soluble CML-collagen 
was confirmed with slower gel mobility (Figure 4; lane 3). Cell lysates were 
collected in SDS-PAGE sample buffer and analysed as described in the Results 
section. 
3.1.4. Measurement of Lysyl Oxidase Protein Levels 
At the end point of experiments studying lysyl oxidase protein levels, cells 
were washed with cold PBS and lysed using the lysis buffer (62.5 mM Tris-HCI, 
2% SDS, 0.71 M ~-mercaptoethanol, and 10% glycerol). Then cell lysates were 
scraped off the plate, collected in a 1.5 centrifuge tube and boiled for 5 minutes. 
Cell lysates were subjected to Western blotting to measure the levels of lysyl 
oxidase. Specifically, samples were separated on a 10% SDS-PAGE gel and 
transferred to a PVDF membrane overnight. Membranes were blocked for 2 
hours in 5% non-fat dry milk in TBST (20 mM Tris-HCI pH 8.0, 150 mM NaCI, 
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0.5% Tween). Membranes were then incubated with an affinity purified rabbit 
anti-lysyl oxidase antibody at a concentration of 1.07 ~g/ml. Rabbit anti-lysyl 
oxidase antibody was prepared (Jeay et a/. , 2003) and affinity purified using a 
CYDTYERPRSGSRHRPG peptide affinity column. This peptide sequence is 
unique and is not shared by any other lysyl oxidase isoform. Membranes were 
washed three times for 15 minutes each in TBST followed by 2 hours incubation 
with an anti-rabbit horseradish peroxidase (HRP) coupled lgG (Cell Signaling 
cat#7074) at a 1:3000 dilution. Membranes were next washed five times for 10 
minutes each. A HyGio Quick spray, which reacts with the conjugated HRP, was 
used to initiate the chemiluminescence reaction, which its intensity was recorded 
on X-ray film (HyBiot, Denville Scientific). The exposure time of the X-ray films to 
the membranes were optimized to determine the ideal saturation intensity of 
bands. The membranes were stripped using Restore Western Stripping Solution 
(Pierce) and re-probed with anti-~-actin antibody (Cell Signaling cat#4970S) for 
loading control. 
Digital photos from the X-ray films were captured using a VersaDoc 
Imaging System (Biorad). Densitometry analysis was carried using the gel 
analyzer feature of the Image J software (http://rsbweb.nih.gov/ijl) according to 
the user manual (IJ version 1.46r, section 30.13). The lysyl oxidase protein levels 
were reported as a ratio of lysyl oxidase band to ~-actin band intensity levels. 
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3.1.5. Knocking Down Discoidin Domain Receptor 2 
A set of 5 Discoidin Domain receptor 2 (DDR2) shRNAs (Open 
Biosystems cat# RMM4534) was screened in both rat and mouse osteoblasts. 
TRCN0000023549 clone (target sequence: CCACCTATGATCCCATGCTIA) for 
mouse osteoblasts and TRCN0000023553 clone (target sequence: 
GCCTCTGGTATGAAGTACCTI) for rat osteoblasts were selected since these 
clones had maximum effects on the reduction of DDR2 protein levels. Anti-DDR2 
antibody (Abeam cat#ab126773) was used at a 1:1000 dilution in the Western 
blot analysis. Lentiviral transduction of primary osteoblasts was executed as 
follows: Human 293T cells were transfected with either DDR2 shRNA plasmid or 
scrambled shRNA (target sequence: CCTAAGGTIAAGTCGCCCTCG; Addgene 
cat#1864) plasmid, in the presence of the packaging plasmids (pCMV-VSV-G 
and pCMV-dR8.2 dvpr; Addgene cat#8454 and cat#8455), using FuGene 6 
(Roche# 11914443001). Media containing viral particles were collected on days 
3 and 5 post-transfection. Collected media were pooled and centrifuged at 
40,000 x g and the viral pellet was suspended in a small volume of PBS. DDR2 
shRNA or scrambled shRNA viral particles titration analysis in the presence of 4 
j.Jg/ml puromycin indicated an optimal dose of 19 x 108 transduction unitlml 
(TU/ml) for 1 x 106 primary osteoblasts (Geraerts et a/., 2006). In knockdown 
experiments, the primary osteoblasts were transduced with DDR2 shRNA or 
scrambled shRNA at 80-90% visual confluence for 24 hours. The medium was 
then refreshed and contained, in addition, 4 j.Jg/ml puromycin to select for 
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transduced cells. After two days, transduced cells were serum-depleted for 18 
hours and treated with vehicle or collagen for 24 hours prior to collecting cell 
layers total proteins. In experiments performed with differentiated cells, the 
shRNA was transduced just before culturing cells in the differentiation medium 
without loss of cell viability. 
3.1.6. Binding Analysis of Glycated Collagen to Discoidin Domain receptor 
2 
A previously published collagen-DDR2 binding assay was employed with 
modifications (Leitinger, 2003). Control collagen or CML-collagen (1 00 !JL at 10 
!Jg/ml per well in PBS) was immobilized on a 96-well plate overnight at room 
temperature. After washing (PBS containing 0.05% Tween 20), wells were 
blocked with 150 !JL of 1 mg/ml BSA in PBS for 1 hour at room temperature. 
Recombinant DDR2-(His)6 (30 pmole) (Creative Biomart cat#773M) was serially 
diluted in the incubation buffer (PBS with 0.5 mg/ml BSA) in a final volume of 50 
!JL and added to each well. Recombinant DDR2-(His)6 consist of the extracellular 
domain of human DDR2 receptor, which is 96% homologous to both mouse and 
rat DDR2. The plate was incubated at room temperature for 3 hours on a gently 
shaking horizontal rotator. Wells were washed 6 times with the washing buffer, 
and incubated for 2 hours with 1 :2000 diluted HRP conjugated anti-His6 antibody 
(Abeam cat#22226) in the incubation buffer in a final volume of 50 !Jl. The level 
of bound DDR2 was detected using 100 !JL of chromogenic substrate 
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(tetramethylbenzidine) (Pierce cat#4301). The reaction was stopped with 100 IJL 
of 2 M sulfuric acid after 20 minutes. Absorbance of samples at 450 nm was 
determined with a Berthold TriStar LB 941 plate reader. All binding assays were 
carried out in six replicates and showed less than 15% variation. 
Independent control analyses confirmed that the wells contained 
equivalent levels of bound control and CML-collagen. Specifically, control- and 
CML-collagen were biotinylated using an EZ-Iink Amine-PEG2-Biotin (Pierce 
cat#21346). The ratio of biotinylated CML-collagen to control-collagen was 1.96 
since EZ-Iink Amine-PEG2-Biotin connects a molecule of biotin to the carboxy 
termini, which is more abundant in CML-collagen compare to control-collagen. 
Next, to quantitate the levels of bound control-and CML-collagen to a 96-well 
plate, an equal amount of Biotinylated control- and CML-collagen were 
immobilized on a 96-well plate (24 wells per group) overnight. Wells were then 
washed five times with PBS containing 0.05% Tween 20, and were incubated 
with an anti-biotin HRP conjugated (Cell signaling cat#7075) for 2 hours. Next, 
the plate was washed five times and the levels of HRP were detected using a 
chromogenic substrate (tetramethylbenzidine) kit. The ratio of bound biotinylation 
CML-collagen to control-collagen was 2, which indicates equal amount of bound 
CML-collagen and control-collagen given that the degree of biotinylation was 
about twice in CML-collagen compared to control-collagen. 
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3.1.7. Sandwich ELISA to Measure the Activation of DDR2 Signaling 
Non-differentiating mouse primary osteoblasts were treated with 0.2 mg/ml 
collagen or CML-collagen, and then lysed (1% NP-40, 20 mM Tris (pH 8.0), 137 
mM NaCI, 10% glycerol, 2 mM EDTA, 1 mM activated (boiled for 10 minutes) 
sodium orthovanadate, 1:100 Sigma proteinase inhibitor cocktail). Total protein 
was measured using the BCA assay (Pierce cat#23225), and aliquots (15 1-Jg) 
were used in ELISA assays for phosphorylated DDR2 and total DDR2 (R&D 
system ELISA kits #DYC6170 and #DYC2538, respectively). The capture anti-
DDR2 antibody (100 1-JL of 4 1-Jg/ml in PBS) was immobilized on a 96-well plate 
(Costar Cat# 2592) overnight at the room temperature. After five washes of 400 
1-JL each with PBS containing 0.05% Tween 20, the plate was blocked with the 
blocking buffer (PBS containing 1% BSA) for three hours. Next, wells were 
washed once and cell lysates or known amounts of phosphorylated recombinant 
DDR2 standards were applied. The plate was incubated at room temperature for 
5 hours and then washed five times. HRP-conjugated phospho-DDR2 detection 
antibody (1 :2000) was added and incubated for three hours. The plate was next 
washed six times before incubating with the chromogenic substrate 
(tetramethylbenzidine) to detect the levels of phosphorylated DDR2. The identical 
protocol was followed for determining the levels of total DDR2 in the same 
samples, using anti-DDR2 as the detection antibody and a standard curve made 
with non-phosphorylated DDR2. Finally, amounts of phosphorylated- and total 
DDR2 present in each lysate were calculated. 
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3.2. In-Vivo Experiments 
3.2.1. Induction of Type I Diabetes 
Diabetes was induced in BALB/cByJ mice by five consecutive multiple low 
dose intraperitoneal injections of streptozotocin (STZ) (40 mg/Kg/day) (Like eta/., 
1976; Rossini eta/., 1977). STZ is a broad-spectrum antibiotic, which destroies 
pancreatic~ cells and induce diabetes (Rakieten eta/., 1963). STZ powder (EMD 
cat#572201) was dissolved in 0.1 M sodium citrate buffer solution pH 4.5. The 
control mice were only injected with the equivalent volume citrate buffer (vehicle). 
Mouse tails were dipped into warm tap water for 1 minute in order to increase th 
blood flows. Then using a Goldenrod animal lancet (Medipoint 4mm lancet), the 
tail vein was punctured to collect a drop of blood, which used to measure non-
fasting glucose. The mice were restrained in a mouse tube holder during tail 
blood collection procedure. To establish the non-fasting blood glucose baseline, 
the non-fasting blood glucose levels were measured on day 7 after the first STZ 
injection and using ACCU-CHEK Compact Plus (Roche Diagnostics) . The onset 
of diabetes occurred on day 12 (non-fasting blood glucose of ~250 mg/dl) as 
previously established in our laboratory (Santana eta/., 2003) (Figure 22). 
3.2.2. Calvarial Bone Healing Model 
Calvarial defects (1 mm diameter), one in parietal bone and one in frontal 
bone, were created one week after the onset of diabetes (day 21 after first STZ 
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injection) in order to provide time for formation and accumulation of AGEs (Figure 
21). Specifically, mice were anesthetized using a ketaimine-xylazine cocktail (65 
mg/kg ketamine; 13 mg/kg). After shaving the head, a straight incision was made 
on the head mid-sagittal plane to retract skin and periosteal tissues and to 
expose skull bones. A carbide cylinder square bur (Meisinger cat#BA-2021-010) 
was used to create 1 mm diameter defects under normal saline irrigation using 
Dremel rotary tool at level 1 speed. The flaps were then replaced and sutured 
with polytetrafluoroethylene non-absorbable suture (Cytoplast 
cat#CS0618PREM) . Mice were kept on heating pad during and for 1 hour after 
the surgery. 
Frontal and parietal lesions were studied separately to examine potential 
differences in lysyl oxidase regulation between neural crest-derived (frontal) and 
mesoderm-derived (parietal) osteoblasts since previous studies reported 
embryonic origin specific behaviors in these two lineages of osteoblasts (Behr et 
a/., 2010; Quarto eta/., 2010). 
3.2.3. Isolation of Total RNA From Calvarial Bone Healing Tissue 
Mice were sacrificed on day seven after creating the defects and the skull 
tissue was immediately immersed in RNA Later reagent (Life Sciences 
cat#AM7021). Total RNA was extracted from a pooled sample of three mouse 
tissues (total pooled samples = 3; total number of mice used per group = 9) using 
RNeasy Micro Kit (Qiagen cat# 74004) . Specifically, calvarial bone healing 
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tissues were isolated using a 1.5 mm diameter biopsy punch (Premirer cat# 
9033509). Biopsy samples were pooled in 150 IJI RL T buffer. Samples were 
homogenized with a PowerGen homogenizer (Fisher) for 1 minute at the level 
one speed, while the tube was kept on ice. After homogenizing the tissues in the 
RL T buffer, total RNA was extracted according to the manufacture's protocol. 
3.2.4. Isolation of Total Protein Including Lysyl Oxidase from Calvarial Bone 
Healing Tissues 
Mice were sacrificed on day seven post-surgery and the skull tissues were 
dissected, placed in empty 1.5 centrifuge tubes, immediately snap frozen by 
dipping the sealed tubes in liquid nitrogen and stored at -80° C. Samples from 
staggered surgeries were collected and on the protein extraction day, we used a 
1.5 mm diameter biopsy punch to harvest the calvarial bone healing tissues. 
Biopsy samples from four mice were pooled in 200 IJI of the extraction buffer (4 M 
urea sodium chloride borate (0.150 M NaCI, 0.05 M borate, pH 8.0) buffer. The 
extraction buffer was also supplemented with phenylmethanesulfonylfluoride 
(100mM PMSF in 95% ethanol, freshly made; 0.25 ml in 100 ml of the extraction 
buffer) and Aprotinin (1 IJI per 1 ml of the extraction buffer). Tissue samples were 
then ground and homogenized using a 2 ml Konet mini tissue grinder (Fisher 
cat# K885470-0000). The tissue grinder was kept on dry ice for at least 15 
minutes prior to use. Ground samples in buffer were kept on ice for 1 0 minutes, 
then transferred into cold centrifuge tubes, and spun down at 10,000 X g for 15 
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minutes at 4° C. The supernatant was collected and its total protein was 
measured using a BCA protein quantification kit. The average total protein per 
pool of four mouse calvarial healing bone samples was 132 j..lg. 
3.2.5. Measurement of Lysyl Oxidase mRNA and Enzyme Activity Levels 
3.2.5.1. Lysyl Oxidase mRNA Levels 
Total RNA was extracted from the calvarial bone tissues as explained in 
section 3.2.3. eDNA was synthesized from 1 j..lg total RNA, using TaqMan 
Reverse Transcription Reagents (Applied Biosystems cat#N8080234). cDNAs 
were then subjected to real time PCR analysis (TaqMan gene expression) using 
Applied Biosystems® 7300 Real-Time PCR Systems to measure lysyl oxidase 
mRNA levels. The following TaqMan probes were purchased from Applied 
Biosystems: mouse lysyl oxidase (cat#Mm00495386_m1) and 18S rRNA (cat# 
Hs03003631_g1 ). 
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3.2.5.2. Lysyl Oxidase Enzyme Activity Levels 
A previously established protocol in our laboratory was followed to 
measure lysyl oxidase enzyme activity using Amplex Ultra-Red Fluorescent dye 
(Palamakumbura et a/., 2002). Specifically, equal amount of extracted total 
proteins from calvarial bone healing tissues (see section 3.2.4) were divided into 
two parts. P-aminopropionitrile (BAPN; 0.5 mM in the final volume) was then 
added to one of the two tubes for each sample to inhibit lysyl oxidase enzyme 
activity and to use its readout as a reference in calculating lysyl oxidase enzyme 
activity. Each aliquot was then transferred into a glass tube and mixed with a 
master mix: 1.2 M urea borate buffer (50 mM boric acid, pH 8.2) supplemented 
with 10 mM Diaminopentane, 10 !JM Amplex Red, and 1 unit/ml HRP. The tubes 
next were incubated for 30 minutes at 3rC. Meanwhile various concentrations of 
hydrogen peroxide (H202) ranging from 0-500 nmoles I 250 IJI in the master mix 
was prepared and incubated for 10 minutes at 3rC. All the tubes were protected 
from light all the time. Amplex Red fluorogenic dye reacts with H202 and emits 
fluorescent light. The levels of fluorescent light were detected for each sample 
using a Berthold TriStar LB 941 plate reader. The levels of fluorescent light 
indicate the amount of H202, which was either directly added to the master mix or 
was the byproducts of lysyl oxidase enzyme activity. The standard line was 
plotted according to readouts for various concentrations of H202 (Figure 6). Then 
for each sample, the readout with BAPN was subtracted from readout without 
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BAPN, and converted to equivalent nM H202 according to the equation for the 
line of best fit. The lysyl oxidase enzyme activity levels were reported as nmoles 
H202 /250 J,JI/23 J.Jg total protein. 
3.2.6. Histological Analysis 
Diabetic and non-diabetic mice were sacrificed either on 7 or 14 days after 
' 
the surgery. The skull tissues were fixed in 10% formalin, decalcified for 4 weeks 
in Cal-Ex Decalcifier (Fischer cat#CS510). The Cal-Ex Decalcifier was refreshed 
twice a week. Decalcified samples were dissected, mounted in paraffin and serial 
sectioned. Masson's trichrome and H&E staining were performed on serial 
sections from skull tissue samples. Photos from selected sections with the best 
tissue integrity were taken using an inverted Zeiss microscope under 100 
magnifications. 
3.3. Statistical Analysis 
Student's t-test assuming unequal variances (heteroscedastic) was 
employed for all our analyses (Ruxton, 2006). StatPius:mac program version 
2009 (AnalystSoft Inc.) was used for the statistical analyses. Significance was 
declared at p<0.05. 
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4. Results 
4.1. In-Vitro Experiments 
4.1.1. Collagen Up-Regulates Lysyl Oxidase Protein Levels in Osteoblasts 
To investigate the mechanism underlying the reduced levels of lysyl 
oxidase enzyme-derived collagen cross-links in diabetic bones (Saito et a/., 
2006), we determined the regulation of lysyl oxidase by control- and CML-
collagen in primary osteoblasts. CML-collagen is an advanced glycation end 
product that activates RAGE signaling in osteoblasts, whereas non-glycated 
collagen does not (Aiikhani et a/., 2007). CML-collagen was chemically prepared 
and verified by its slower gel mobility and positive immunoreactivity with an anti-
CML antibody (Figure 3) as explained in section 3.1.3.1. Isolated primary 
osteoblasts were cultured under non-differentiating conditions, serum-depleted 
and then treated with 0.2 mg/ml collagen, CML-collagen, or vehicle for 24 hours 
and cell lysates were subjected to Western blot analyses (Figure 4). Data 
indicate that non-glycated control collagen up-regulated mature lysyl oxidase 
protein 2-fold, while CML-collagen had no effect (Figure 5-6). These data 
suggest that mechanisms other than RAGE signaling are responsible for 
regulating lysyl oxidase protein levels in diabetes. 
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Figure 4. Western Blotting and Gel Mobility Assays Verified the Carboxymethyl 
Lysine Modification of Collagen 
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Figure 4. Western Blotting and Gel Mobility Assays Verified the Carboxymethyl 
Lysine Modification of Collagen 
Type I collagen form calf skin was chemically modified. To verify the 
addition of carboxymethyl lysine to collagen, Western blotting was carried out 
using an anti-CML antibody. Additionally, gel mobility of CML-collagen and 
control-collagen were examined using an 8% SDS-PAGE gel. Lanes 1 and 2 
present the results of Western blotting analysis on 40ng of control-collagen (lane 
1) and CML-collagen (lane 2). The arrows point to the positive immunoreactivity 
of CML-collagen in lane 2 (~. a1, and a2 chains). Lanes 3-5 show Coomassie 
Blue staining of 100 IJg supernatant proteins of centrifuged CML-collagen (lane 
3) and 100 IJg CML-collagen (lane 4) and 1 OO!Jg control-collagen (lane 5). Lane 6 
is the pre-stained protein standard. 
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Figure 5. A Scheme of the Experimental Design to Examine Control- and CML-
Collagen Regulation of Lysyl Oxidase in Non-Differentiated Primary Calvarial 
Osteoblasts 
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Figure 6. Collagen Up-Regulates Lysyl Oxidase in Non-Differentiated Primary 
Mouse Osteoblasts, While CML-Collagen Fails to Induce Lysyl Oxidase 
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Figure 6. Collagen Up-Regulates Lysyl Oxidase in Non-Differentiated Primary 
Mouse Osteoblasts, While CML-Collagen Fails to Induce Lysyl Oxidase 
Non-differentiated primary mouse osteoblasts were serum depleted and 
then treated with collagen (0.2 mg/ml) or CML-collagen (glycated collagen; 0.2 
mg/ml). Total protein was extracted and subjected to Western blotting for mature 
32 kDa lysyl oxidase and P-actin (loading control). The bar graph shows lysyl 
oxidase protein levels in non-differentiated mouse primary osteoblasts in 
response to collagen or CML-collagen (N=3). Data are from one of three 
independent experiments with the same outcome. Data are mean ± SD (*, 
p<0.05; Student's t-test). 
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Figure 7. Collagen Up-Regulates Lysyl Oxidase in Non-Differentiated Primary 
Mouse Osteoblasts, While CML-Collagen Fails to Induce Lysyl Oxidase 
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Figure 7. Collagen Up-Regulates Lysyl Oxidase in Non-Differentiated Primary 
Mouse Osteoblasts, While CML-Collagen Fails to Induce Lysyl Oxidase 
Non-differentiated primary mouse osteoblasts were serum depleted and 
then treated with collagen (0.2 mg/ml) or CML-collagen (glycated collagen; 0.2 
mg/ml). Total protein was extracted and subjected to Western blotting for mature 
32 kDa lysyl oxidase and ~-actin (loading control). The bar graph shows lysyl 
oxidase protein levels in non-differentiated mouse primary osteoblasts in 
response to collagen or CML-collagen (N=3, each N summarizes the mean of an 
independent experiment with triplicates in each group). Data represent the pool 
of three independent experiment means normalized to the vehicle group in each 
experiment. Data are mean± SEM (*, p<0.05; Student's t-test). 
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4.1.2. Lysyl Oxidase Is Not Down-regulated by a RAGE Ligand 
To independently investigate the apparent lack of CML-collagen/RAGE-
mediated down-regulation of lysyl oxidase, we prepared CML-modified albumin, 
a known non-collagenous ligand for RAGE that we and others have previously 
shown activates RAGE (Aiikhani et a/., 2007; Kislinger et a/., 1999) and that 
inhibits bone healing in-vivo (Santana et a/., 2003). CML-BSA modification was 
verified by CML-BSA slower gel mobility and positive immunoreactivity with an 
anti-CML antibody (Figure 7). Our TNBS analysis, as explained in section 
3.1.3.2, indicates 23% modifications of lysine in BSA (Figure 8). Non-
differentiated primary mouse osteoblasts were treated with CML-BSA and control 
non-glycated-BSA for 24 hours (Figure 9). Western blotting analysis showed no 
difference in lysyl oxidase protein levels in cells treated with CML-BSA compared 
to controi-BSA (Figure 1 0), confirming that AGE-initiated signaling does not 
regulate lysyl oxidase protein levels in non-differentiated primary mouse 
osteoblasts. 
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Figure 8. Western Blotting and Gel Mobility Assays Confirmed the 
Carboxymethyl Lysine Modification of Bovine Serum Albumin 
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Figure 8. Western Blotting and Gel Mobility Assays Confirmed the 
Carboxymethyl Lysine Modification of Bovine Serum Albumin 
Fraction V bovine serum albumin (BSA) was chemically modified to 
generate CML-BSA. To verify the addition of carboxymethyl lysine to BSA, 
Western blotting was carried out using an anti-CML antibody. Lanes 1 and 2 
present the results of Western blotting analysis on 40 ng of CML-BSA (lane 1) 
and Controi-BSA (lane 2). Since fraction V of BSA is not entirely pure BSA, Lane 
1 also shows immunoreactivity of other proteins (smear), which have been also 
CML-modified. In addition to Western blotting, gel mobility of CML-BSA and 
controi-BSA were examined using a 10 % SDS-PAGE gel. Lanes 3-6 show 
Coomassie Blue staining of 100 tJg controi-BSA (lanes 3 and 4) and 100 tJg 
CML-BSA (lanes 5 and 6). The arrow points the non-modified BSA. Lane 7 is the 
pre-stained protein standard. 
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Figure 9. Trinitrobenzene Sulfonate (TNBS) Assay Showed That 23% of Lysine 
Residues Are Modified in Bovine Serum Albumin 
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Figure 9. Trinitrobenzene Sulfonate (TNBS) Assay Showed That 23% of Lysine 
Residues Are Modified in Bovine Serum Albumin 
The absorbance readouts from the TNBS assay as a function of various 
concentrations of both CML-BSA and BSA were plotted. The lines of best fit were 
then drawn for both CML-BSA and BSA using GraphPad Prism 5 software. Data 
represent mean ± SO. The plot is the representative of two independent 
experiments with similar outcomes. 
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Figure 10. A Scheme of the Experimental Design to Study Control- and CML-
BSA Regulation of Lysyl Oxidase in Non-Differentiated Primary Calvarial 
Osteoblasts 
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Figure 11. The RAGE Ligand CML-BSA Does Not Down-Regulate Lysyl Oxidase 
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Figure 11. The RAGE Ligand CML-BSA Does Not Down-Regulate Lysyl Oxidase 
Non-differentiated primary mouse osteoblasts were serum-depleted and 
then treated with BSA (0.2 mg/ml) or CML-BSA (0.2 mg/ml) for 24 hours and 
subjected to Western blotting for mature 32 kDa lysyl oxidase and j3-actin 
(loading control). Data are representative of two independent experiments with 
the same outcome. Data are mean± SO(*, p<0.05; Student's t-test). 
53 
4.1.4. DDR2 Mediates Collagen Induction of Lysyl Oxidase 
To elucidate the mechanism by which collagen up-regulates lysyl oxidase in 
non-differentiated primary mouse osteoblasts, we investigated roles for different 
collagen receptors. Discoidin Domain Receptor-2 and collagen-binding integrins 
(a1 P1 , a2P1, a1 OP1, and a11 P1) represent two distinct collagen receptor classes 
in bone. 
The ability of DDR2 to mediate collagen up-regulation of lysyl oxidase in 
osteoblasts was evaluated using a lentiviral shRNA against DDR2 as explained 
in section 3.1.5. Isolated primary osteoblasts were transduced with lentiviral 
particles containing DDR2 or scrambled (control) shRNA. DDR2 protein levels 
were reduced by - 60% with DDR2 shRNA compared to cells transduced with a 
scrambled shRNA (Figure 12A). The transduced cells were next treated with 0.2 
mg/ml of collagen or the vehicle for 24 hours (Figure 11). Western blots of cell 
layer extracts indicate that lysyl oxidase protein levels were - 60% inhibited in 
DDR2 knocked-down osteoblasts in response to collagen compared to collagen-
stimulation of lysyl oxidase in the control cells (Figure 128). These data indicate 
that collagen induction of lysyl oxidase is mediated by DDR2. Taken together, 
data presented above constitute the first direct determination that collagen 
regulates lysyl oxidase, and that this regulation is mediated by DDR2. 
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Figure 12. A Scheme of the Experimental Design to Investigate the Role of 
DDR2 in Lysyl Oxidase Regulation by Collagen in Non-Differentiated Primary 
Mouse Osteoblasts 
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Figure 13. Collagen Up-regulates Lysyl Oxidase via Discoidin Domain Receptor 
2 (DDR2) in Non-Differentiated Primary Mouse Osteoblasts 
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Figure 13. Collagen Up-regulates Lysyl Oxidase via Discoidin Domain Receptor 
2 (DDR2) in Non-Differentiated Primary Mouse Osteoblasts 
Primary mouse osteoblast cultures were transduced with DDR2 shRNA 
lentivirus and a scrambled control shRNA lentivirus. Cells were serum-depleted 
and then treated with collagen (0.2 mg/ml) for 24 hours and cell layer proteins 
were subjected to Western Blotting for DDR2 and mature 32 kDa lysyl oxidase. 
Data are means +/- SO, (*, p<0.05; N=3) from one of two representative 
experiments with the same outcomes. 
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4.1.3. lntegrins May Cooperate with DDR2 in the Up-Regulation Of Lysyl 
Oxidase by Collagen 
For the second class of collagen-binding receptors, we focused on 
integrins, and employed 2 mM EDTA, which inhibits all integrin signaling in live 
cells (Knight et a/., 2000). Cells were treated as described above with control 
collagen in the presence and absence of EDTA (Figure 13). Western blot 
analyses of cell layers indicate that collagen up-regulated lysyl oxidase protein 
levels attenuate in the presence of EDTA (Figure 14A). 
To verify that EDTA in fact inhibited collagen-stimulated integrin signaling, 
activation of downstream focal adhesion kinase (FAK) was measured in the 
presence and absence of EDTA. FAK phosphorylation on Tyr-576fTyr-577 was 
used as an index of collagen-induced integrin activation (Calalb et a/., 1995; 
Ohkawa eta/., 2010). Anti-phospho-FAK (Ty576/577) and anti-FAK antibodies 
were purchased from Cell Signaling and used at a dilution of 1:1000. Western 
blot analysis showed that EDTA mostly inhibited collagen-stimulated FAK 
phosphorylation optimally after 9 hours of collagen treatment (Figure 148). 
Overall, our studies indicated that collagen does not up-regulate lysyl 
oxidase in DDR2 knock down osteoblasts. In addition, it has been recently 
reported that collagen-binding integrins cooperate with DDR2 in cell adhesion to 
collagen (Xu et a/., 2012). Thus, our results collectively suggest that collagen 
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binding to DDR2, potentially with integrins cooperation, mediates the collagen 
up-regulation of lysyl oxidase in osteoblasts. 
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Figure 14. A Scheme of the Experimental Design to Study the Collagen Up-
regulation of Lysyl Oxidase While Inhibiting Collagen-lntegrins Binding by EDTA 
in Non-differentiated Primary Calvarial Osteoblasts 
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Figure 15. Collagen-Binding lntegrins Cooperate with DDR2 to Mediate Collagen 
Up-regulation of Lysyl Oxidase in Non-differentiated Primary Mouse Osteoblasts 
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Figure 15. Collagen-Binding lntegrins Cooperate with DDR2 to Mediate Collagen 
Up-regulation of Lysyl Oxidase in Non-differentiated Primary Mouse Osteoblasts 
Non-differentiated primary mouse osteoblasts were serum-depleted and 
then treated with collagen (0.2 mg/ml) for 24 hours (A) or 9 hours (B) in the 
presence or absence of 2 mM EDT A. (A) Cell layer protein was extracted and 
subjected to Western blotting for mature 32 kDa lysyl oxidase and 13-actin 
(loading control). Data are means +/- SD, (*, p<0.05; N=3; Student's t-test) from 
one of two representative experiments with the same outcomes. (B) Western 
blotting for Tyr-576/Tyr-577 phosphorylated FAK, total FAK, and 13-actin (loading 
control). Data are means +/- SD and from one experiment in triplicate, (*, 
p<0.05; N=3; Student's t-test) . 
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4.1.5. Glycation of Collagen Interferes with Its Binding to DDR2 
We next reasoned that glycation of collagen could interfere with collagen-
DDR2 binding and thereby block its ability to up-regulate lysyl oxidase in 
osteoblasts. To examine this idea, we compared recombinant DDR2 (rDDR2) 
binding to collagen and CML-collagen. Control non-glycated and glycated 
collagens first were respectively immobilized on 96-well plates and incubated 
with increasing amounts of soluble rDDR2. Independent control analyses 
confirmed that the wells contained equivalent levels of bound control and CML-
collagen (see section 3.1.6). The extent of rDDR2 binding to non-glycated control 
and glycated collagen were measured as explained in the Materials and Methods 
(see section 3.1.6). Data (Figure 15) reveal that DDR2 binding to collagen far 
exceeded its ability to bind CML-collagen above 10 pmoles/well. DDR2 binding to 
CML-collagen was only 40% of the level bound to collagen at 30 pmol DDR2 
(Figure 15). These data support that glycation of collagen interferes with 
DDR2/collagen binding. 
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Figure 16. Glycation of Collagen Interferes with Collagen-DDR2 Binding 
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Figure 16. Glycation of Collagen Interferes with Collagen-DDR2 Binding 
Collagen or CML-collagen (1 0 !Jg/ml) was coated on wells of a 96-well 
plate. Increasing amounts of horseradish peroxidase-conjugated recombinant 
DDR2 was incubated for three hours at room temperature. The plate was 
washed and the relative levels of bound rDDR2 were measured utilizing a 
chromogenic substrate (Materials and Methods; see section 3.1.6). Data show 
binding curves for rDDR2 to collagen (solid line) and rDDR2 to CML-collagen 
(dotted line) and are means +/- SO (N=6; p<0.05). Data are from one of two 
experiments with the same outcomes. 
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4.1.6. CML-collagen Does Not Activate Collagen-DDR2 Signaling 
In order to verify the results of the binding assays, we next assessed the 
activation of the collagen-DDR2 axis by determining the degree of DDR2 tyrosine 
phosphorylation as a function of collagen or CML-collagen treatment. DDR2 
phosphorylation, unlike that of other tyrosine receptor kinase receptors, occurs 
with slow and sustained kinetics of phosphorylation detectable 30 minutes after 
ligand binding and remains at a high steady-state level for at least 18 hours 
(Vogel, 1999). Non-differentiated primary mouse osteoblasts were treated with 
0.2 mg/ml collagen, CML-collagen or vehicle for 5 hours following serum 
starvation. Total cell layer proteins were subjected to ELISA analysis for tyrosine-
phosphorylated DDR2 and total DDR2 (Materials and Methods; see section 
3.1. 7). Data (Figure 16) show a robust DDR2 phosphorylation following treatment 
with control non-glycated collagen, while no increased DDR2 phosphorylation 
was seen in response to CML-collagen. 
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Figure 17. Glycated Collagen Does Not Activate Collagen-DDR2 Signaling 
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Figure 17. Glycated Collagen Does Not Activate Collagen-DDR2 Signaling 
Non-differentiated primary mouse osteoblasts were serum-depleted and 
then treated with collagen (0.2 mg/ml). Total protein was extracted, and the 
phospho-DDR2 levels were measured by a phospho-DDR2 ELISA kit. Collagen 
increased phospho-DDR2, while CML-collagen did not induce DDR2 
phosphorylation. Data are from one of two independent experiments with the 
same outcomes (N=3; *, p<0.05; Student's t-test). 
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4.1.7. Collagen Up-regulates Lysyl Oxidase in Differentiated Mouse and Rat 
Primary Osteoblasts 
We next sought to determine whether these mechanisms for lysyl oxidase 
regulation occur during osteoblast differentiation. Differentiating osteoblasts were 
treated with collagen and CML-collagen (Experimental Procedures). Our 
previous studies indicated that 7 days of differentiation was the optimal time point 
to observe collagen-mediated up-regulation of lysyl oxidase (Hong eta/., 2004). 
Thus, 7 -day differentiated cells were treated with control non-glycated collagen 
and CML-collagen as described previously for non-differentiated mouse and rat 
osteoblasts (Figure 17). Data indicate that collagen induced lysyl oxidase protein 
levels more than two-fold, while CML-collagen failed to regulate lysyl oxidase 
(Figure 18). 
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Figure 18. A Scheme of the Experimental Design to Investigate the Regulation of 
Lysyl Oxidase by Collagen and CML-Collagen in Differentiated Primary Mouse 
and Rat Osteoblasts 
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Figure 19. Collagen Up-regulates Lysyl Oxidase in Differentiated Primary Rat 
and Mouse Osteoblasts 
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Figure 19. Collagen Up-regulates Lysyl Oxidase in Differentiated Primary Rat 
and Mouse Osteoblasts 
Differentiated primary mouse (A) , and rat (B), osteoblasts were serum 
starved and then treated with collagen (0.2 mg/ml) or CML-collagen (0.2 mg/ml) 
for 24 hours followed by Western blotting of cell layer extracts for mature 32 kDa 
lysyl oxidase and f3-actin (loading control). In both A and B, data are means +/-
SO and are from one of three independent experiments (N=3; *, p<0.05; 
Student's t-test). 
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We next examined differentiated rat osteoblasts to determine the role of 
RAGE and integrin receptors in regulation of lysyl oxidase by using a non-
collagen glycated protein known to activate RAGE (CML-BSA) . As expected, 
CML-BSA and non-glycated-BSA did not alter lysyl oxidase levels (Figure 19A). 
Similarly, lysyl oxidase was not regulated by non-glycated collagen or CML-
collagen in the presence of a RAGE-neutralizing antibody (Figure 198). 
Next, to confirm the absence of a role for integrins in collagen induction of 
lysyl oxidase in differentiated primary rat osteoblasts, the cells were serum-
depleted and treated with 0.2 mg/ml of non-glycated collagen or vehicle for 24 
hours in the presence or absence of 2 mM EDT A. Data indicate that lysyl oxidase 
was up-regulated by collagen similarly in the presence and absence of EDTA, 
confirming that the collagen-integrin axis may not be responsible for collagen-
mediated lysyl oxidase up-regulation in differentiated primary rat osteoblasts 
(Figure 19C). This is in contrast with the partial function of integrin signaling in 
non-differentiated mouse osteoblasts, which could propose that the collagen up-
regulation of lysyl oxidase mediates by different signaling pathways as a function 
of osteoblasts differentiation. 
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Figure 20. Collagen Induction of Lysyl Oxidase in Differentiated Rat Osteoblasts 
Is Independent of both (A And B) AGE-RAGE Signaling , and (C) lntegrin 
Signaling 
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Figure 20. Collagen Induction of Lysyl Oxidase in Differentiated Rat Osteoblasts 
Is Independent of both (A And B) AGE-RAGE Signaling, and (C) lntegrin 
Signaling 
(A) Rat calvarial osteoblasts were cultured and permitted to differentiate 
for 7 days. (A) Cells were serum depleted and then treated with BSA (0.2 mg/ml) 
or CML-BSA (0.2 mg/ml) for 24 hours. Western blot analysis for mature 32 kDa 
lysyl oxidase and 13-actin (loading control) was performed on cell layer extracts. 
(B) Differentiated and serum-depleted rat osteoblasts were cultured with 10 
JJg/ml anti-RAGE antibody or non-immune lgG for 30 minutes followed by 
collagen (0.2 mg/ml) for 24 hours and subjected to Western blotting for mature 
32 kDa lysyl oxidase and 13-actin (loading control). Neutralizing anti-RAGE 
(cat#8230) and normal goat lgG (cat#S2028) antibodies were purchased from 
Santa Cruz Biotechnology. (C) Differentiated and serum-depleted rat osteoblasts 
were treated with collagen (0.2 mg/ml) for 24 hours in the presence or absence 
of 2 mM EDT A. Cell layer protein was extracted and subjected to Western 
blotting for 32 kDa lysyl oxidase and 13-actin (loading control). For A, B, and C 
data shown are from one of two experiments, each performed in triplicate (N=3; 
*, p<0.05; Student's t-test). 
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4.1.8. DDR2 Mediates Collagen Induction of Lysyl Oxidase in Differentiated 
Primary Rat Osteoblasts 
Differentiated primary rat osteoblasts were next tested for the role of DDR2 
in collagen induction of lysyl oxidase. Non-differentiated cells were first 
transduced with lentiviral particles containing DDR2 shRNA or scrambled shRNA 
and transduced cells were selected with puromycin. After seven days of 
differentiation of confluent cultures, cells were treated with collagen and CML-
collagen as above (Figure 20). DDR2 knockdown was 70% as determined by 
Western blotting (Figure 21A); and data showed that collagen failed to induce 
lysyl oxidase in DDR2 knock-down differentiated primary rat osteoblasts (Figure 
218). Collagen up-regulates lysyl oxidase in differentiated control osteoblasts 
(transfected with the scrambled shRNA) although this up-regulation was not 
statically significant. 
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Figure 21. A Scheme of the Experimental Design To Examine the Role of DDR2 
in Lysyl Oxidase Regulation by Collagen in Differentiated Rat Osteoblasts 
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Figure 22. Collagen Up-regulation of Lysyl Oxidase in Differentiated Primary Rat 
Osteoblasts Is Mediated by DDR2 
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Figure 22. Collagen Up-regulation of Lysyl Oxidase in Differentiated Primary Rat 
Osteoblasts Is Mediated by DDR2 
DDR2 was knocked downed in non-differentiated primary rat osteoblasts 
using shRNA lentivirus technology. Transduced cells were differentiated for 
seven days, serum starved and then treated with collagen (0.2 mg/ml) for 24 
hours. Cell layer protein was extracted and subjected to Western blotting for 32 
kDa lysyl oxidase and P-actin (loading control). Data (means +/- SO) are from 
one of two experiments each performed in triplicate with the same outcome (N=3; 
*, p<0.05; Student's t-test). 
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4.1.9. Summary of In-Vitro Studies 
Taken together, data demonstrate that in non-differentiation and 
undergoing differentiation mouse and rat primary osteoblasts, collagen regulates 
lysyl oxidase. In order to understand the mechanism of collagen up-regulation of 
lysyl oxidase, we investigated roles for the major classes of collagen receptors: 
integrins and Discoidin Domain Receptors. We showed that DDR2, likely in 
cooperation with integrins, functions to mediate collagen regulation of lysyl 
oxidase. Moreover, we demonstrated that collagen glycation at physiological 
levels fails to bind and activate DDR2 signaling. 
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4.2. In-Vivo Experiments 
Figure 22 summarizes the in-vivo experimental design. 
4.2.1. Descriptive Analyses of Weight and Non-Fasting Blood Glucose in 
Diabetic and Non-Diabetic Mice 
We measured the weight of mice at 0, 7, 14, 21, and 28 days post first 
STZ injection. Figure 23A shows that STZ prompts weight loss (mean ± SEM) in 
the first week after the first injection; however, diabetic mice regain this loss later. 
The weight difference between diabetic and non-diabetic mice at day 28 was 
approximately 1.9 grams. Figure 238 displays the weights of all mice. Non-
fasting blood glucose was measured with ACCU-CHEK Compact Plus (Roche 
Diagnostics). Figure 23C shows the increase of blood glucose (mean ± SEM) as 
a function of time; the green dotted-line represents the blood glucose threshold 
used to define diabetes (250 mg/dl). Figure 230 represents the blood glucose of 
all mice. N=30 for the diabetic mice and N=28 for the non-diabetic group. Mice in 
the diabetic group that did not reach the threshold were excluded from the study 
before the surgical procedure. 
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Figure 23. A Scheme for the Chemical Induction of Type I Diabetes and the 
Experimental Design of In-Vivo Studies in Diabetic Mice 
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Figure 24. Descriptive Analyses of Weight and Non-Fasting Blood Glucose in the 
Diabetic and Non-Diabetic Mice 
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4.2.2. Diabetes Up-Regulates Lysyl Oxidase mRNA and Enzyme Activity 
Levels in Both Frontal and Parietal Bone in Early Stage of Healing (Day 7) 
Defects were created in diabetic and non-diabetic mice (21 days after the 
first injection). On day 7 post-surgery, total RNA and total protein were isolated 
from bone healing tissues in diabetic and non-diabetic mice (see section 3.2.3). 
Lysyl oxidase mRNA and enzyme activity levels were assessed using real-time PCR and 
a fluorometric assay, respectively , as explained in section 3.2.4. We found that on day 
7 of bone healing, lysyl oxidase mRNA levels in both frontal and parietal bone 
increased under diabetic conditions (Figure 24). 
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Figure 25. Lysyl Oxidase mRNA and Lysyl Oxidase Enzyme Activity Are Up-
Regulated in Calvarial Healing Bone Under Diabetic Conditions 
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Figure 25. Lysyl Oxidase mRNA and Lysyl Oxidase Enzyme Activity Are Up-
Regulated in Calvarial Healing Bone Under Diabetic Conditions 
(A) The chart shows lysyl oxidase mRNA levels of healing calvarial bone 
on day 21 after first STZ injection in diabetic and non-diabetic mice. Mice were 
sacrificed on day seven after creating the defects. Total RNA was extracted from 
a pooled sample of three mice tissues (total pooled samples = 3; number of mice 
per group = 9) and real time PCR was employed to measure lysyl oxidase mRNA 
levels normalized to 18S rRNA. Data are means ± SEM {N=3; *, p<0.05; 
Student's t-test). (B) The chart represents lysyl oxidase enzyme activity levels in 
the frontal and parietal healing bone in diabetic and non-diabetic mice. Mice were 
sacrificed seven days after defects were made. Lysyl oxidase protein was 
extracted from a pooled sample of four mice tissues with 3 pools per group (N=3 
with 12 mice/group). Lysyl oxidase enzyme activities were assessed as 
explained in the section 3.2.5.2. Data are means ± SEM; (N=3; *, p<0.05; 
Student's t-test) 
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4.2.3. Diabetes Results in Formation of a Fibrotic Matrix in Bone Healing 
Tissues 
In order to further understand the up-regulation of lysyl oxidase in diabetic 
bone healing, we sought to perform histological analyses on the early (day 7) and 
late (day 14) stages of bone healing tissues. We chemically induced diabetes in 
8-week old mice. Defects were created in diabetic and non-diabetic mice (21 
days after first injection). Mice were euthanized at one or two weeks after the 
surgery. Skulls of these mice were fixed and decalcified as explained in section 
3.2.6. Decalcified samples were dissected, mounted in paraffin and serial 
sectioned to stain with Masson's trichrome and H&E. Representative histological 
sections showed inhibited bone formation in diabetic defects. Specifically, 
sections from day 7 post-surgery in diabetic mice contained hematomas (red 
arrow) - in the slower healing parietal defects - which was not seen in the 
controls at this time point (Figure 25). Frontal defects contained primarily excess 
non-mineralizing extracellular matrix (Figure 25, green arrow). As we previously 
reported, diabetes interferes with bone formation in parietal bone. Purple arrows 
in figure 23 mark newly formed bone tissue on day 14 post-surgery in non-
diabetic mice, which is absent in diabetic mice. These histological observations 
collectively suggest that hematomas, which form in the initial stage of bone 
healing, do not resolve in diabetic mice. Moreover, an accumulation of excess 
non-mineralized fibrotic extracellular matrix in diabetic mice seemed to 
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accumulate in the interstitial bone healing tissues and likely interferes with the 
normal course of bone healing. 
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Figure 26. Histological Analysis Showed an Excess Formation of Fibrotic Matrix 
in the Diabetic Mice 
0 
:; 
..c 
., 
c 
C: 
0 
z 
0 
~ 
., 
q 
Cranium 
Cranium 
7-days Frontal Bone Healing 
f.:M.- Cr~~ntum 
14-days Frontal Bone Healing 
g t t 
z 
0 
:; 
..c 
., 
c 
Cnmlum 
Cranium 
H&E 
Staining 
~- Cranium - ; 
Masson's Trichrome 
Staining 
89 
Cranium 
Cranium 
Cranium 
7-days Parietal Bone Healing 
___ .:;;;-·;.::•11 Cr.ilnlum 
14-days Parietal Bone Healing 
- :':..i" Cranlwn .-.:..-
H&E 
Staining 
Masson's Trichrome 
Staining 
Figure 26. Histological Analysis Showed an Excess Formation of Fibrotic Matrix 
in the Diabetic Mice 
Diabetic and non-diabetic mice were sacrificed either 7 or 14 days after 
the surgery. Skull tissues were fixed in 10% formalin and decalcified for one 
month as explained in 3.2.6. Samples were serially sectioned and these sections 
were stained with Masson's trichrome and H&E staining. Photos were taken at 
1 OOX magnification. The scale bars indicate 0.2 mm. The photos are 
representative of histological analysis from diabetic (N=1 0, 5 mice in day 7 group 
and 5 mice in day 14 group) and non-diabetic (N=11, 6 mice in day 7 group and 5 
mice in day 14). 
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4.2.4. Summary of In-Vivo Studies 
Our in-vivo experiments indicate an up-regulation of lysyl oxidase mRNA 
and enzyme activity levels in calvarial bone healing tissues in diabetic mice. 
Additionally, histological analyses on the early (day 7) and late (day 14) stages of 
calvarial bone healing suggested that unresolved hematomas and/or 
accumulation of excess non-mineralized fibrotic-like matrix could partly contribute 
to the impaired calvarial bone healing in diabetic mice. 
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5. Discussion 
Cellular and ECM abnormalities in diabetes have contributed to diabetic 
bone fragility. Cellular pathologies interfere with bone remodeling and 
homeostasis resulting in diminished bone formation, which consequently leads to 
weak bones in diabetes. Furthermore, the accumulation of glycated collagen, the 
prime constituent of bone organic extracellular matrix, disrupts the bone structure 
and thereby reduces bone strength in diabetes. The second extracellular 
abnormality is the reduced levels of lysyl oxidase enzyme-dependent collagen 
cross-links in diabetic bones, which were discovered in studies on rat diabetic 
bones and can explain diabetic poor bone quality (Saito eta/., 2006). Studies on 
diabetic rat bones, however, did not directly investigate the regulation of lysyl 
oxidase in osteoblasts as a function of diabetes. Therefore, we sought to 
determine the regulation of lysyl oxidase in bone under diabetic conditions. 
Here we provide evidence for novel mechanisms of diabetic bone fragi lity 
as well as impaired intramembranous bone healing in diabetes. Our in-vitro 
studies revealed that collagen-DDR2 signaling up-regulates lysyl oxidase levels. 
Moreover, collagen that has been non-enzymatically glycated, as is typical in 
diabetes, fails to promote lysyl oxidase production by osteoblasts mainly by 
disturbing collagen-DDR2 binding. The lack of lysyl oxidase regulation in 
diabetes can partially explain bone fragility in diabetes. 
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Our in-vivo studies on intramembranous bone healing in diabetic mice 
suggest that under diabetic conditions a non-mineralized fibrotic tissue forms 
during calvarial intramembranous bone healing, which inhibits intramembranous 
bone-formation in diabetes. 
5.1. In-Vitro Studies 
5.1.1. Collagen Up-Regulates Lysyl Oxidase in Osteoblast and Glycated 
Collagen Fails to Regulate Lysyl Oxidase in These Cells 
This is the first report showing that collagen up-regulates lysyl oxidase in 
osteoblasts, and likely other types of cells. As explained in the introduction, lysyl 
oxidase is a required enzyme for the formation of collagen cross-links, which 
stabilizes collagen fibrils. The lack of lysyl oxidase enzyme-dependent collagen 
cross-links, which was shown in studies inhibiting lysyl oxidase activity, leads to 
osteolathyrism (weak bones). Given the importance of lysyl oxidase in bone 
physiology, our finding that collagen regulates lysyl oxidase in osteoblasts 
provides a new cellular mechanism by which the interaction of bone extracellular 
organic matrix particularly collagen with bone-forming cells (osteoblasts) 
regulates the strength of bone. 
In addition, our studies indicate that collagen glycation inhibits the up-
regulation of lysyl oxidase by collagen in primary osteoblasts. This finding 
suggests a mechanism explaining reduced lysyl oxidase enzyme-dependent 
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collagen cross-links in diabetic bones, which along with diminished bone 
formation induce bone fragility in diabetes. 
5.1.2. DDR2 Mediates the Lysyl Oxidase Regulation by Collagen 
In order to understand the mechanism of collagen up-regulation of lysyl 
oxidase, we investigated roles for the major classes of collagen receptors: 
Discoid in Domain Receptors and collagen-binding integrins (a1 ~1, a2~1, a1 0~1, 
anda11~1). 
We demonstrate that DDR2, a receptor expressed on a variety of 
mesenchymal cells (Alves eta/., 1995), functions to mediate collagen regulation 
of lysyl oxidase. The DDR2-mediated lysyl oxidase induction in osteoblasts 
reported here is a novel function for this receptor. 
Various functions have been reported for DDR2. In an in-vitro study, 
Zhang and colleagues showed that DDR2 activation leads to Runx2 
phosphorylation, which regulates osteoblast differentiation in pre-osteoblasts 
(Zhang eta/., 2011). 
Mice in which DDR2 has been knocked out show abnormal post-natal 
bone growth and development (Labrador eta/., 2001); diminished chondrocyte 
proliferation was shown as a mechanism explaining this bone phenotype. 
However, craniofacial deformities associated with DDR2 -/- mice (Dullin et a/., 
2007) indicate other potential possibilities as well, since craniofacial skeletal 
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growth and development is mostly based on intramembranous osteogenesis, 
which lacks the transient cartilage formation phase (Gilbert, 2000). 
DDR2 mutated mice (S/ie/Siie) , similar to DDR2 null mice, present with 
post-natal growth abnormalities in craniofacial and long bones. This spontaneous 
autosomal-recessive mutation was mapped to an approximately 150 Kbp 
deletion that extended into the DDR2 gene (Kano eta/., 2008). The mutated mice 
presented with gonadal dysfunction as well. The authors showed no difference in 
all the hormones secreted from the pituitary gland in S/ie/Siie mice, which ruled 
out a central mechanism, namely hypopituitarism, for post-natal growth 
abnormalities and gonadal dysfunction in Slie/Siie mice. Next, the disturbed 
DDR2 signaling in gonads (a peripheral tissue-specific defect) was shown to 
prompt gonadal dysfunction in S/ie/S/ie mice. This report did not investigate 
mechanisms behind skeletal retardation and deformities beyond eliminating a 
potential central hormonal mechanism (hypopituitarism). 
Our findings that DDR2 mediates collagen regulation of lysyl oxidase 
provide a new potential mechanism for skeletal complications, which occur in 
both DDR2 deficient and mutant mice. Our findings combined with studies of 
DDR2 mutant mice, suggest that DDR2 regulates various cellular and 
extracellular events in bone growth and development, some of which may 
depend on lysyl oxidase. 
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5.1.3. Glycated Collagen Does Not Interact with DDR2 
We show that glycated collagen at physiological levels fails to bind and 
activate DDR2 signaling. McCarthy eta/. previously showed reduced binding of 
rat osteosarcoma-derived cells (UMR106) to glycated collagen. The authors 
showed that glycated collagen does not compete with RGD and DGEA peptides 
(specific sequence for a1 ~1 and a2~1 integrins), and proposed that glycation of 
collagen interferes with different collagen-integrin binding sites (McCarthy et a/., 
2004). 
Based on our current study, we suggest that loss of collagen interaction 
with DDR2 under diabetic conditions could potentially also contribute to the 
observed loss of cell adhesion. Leitinger group's recent study that showed DDR2 
and collagen-binding specific integrins cooperate in cell adhesion support this 
notion (Xu eta/., 2012). 
5.1.4. Collagen-lntegrin Binding May Cooperate with Collagen-DDR2 
Signaling to Induce Lysyl Oxidase in Osteoblasts 
The second series of experiments to determine the mechanisms behind 
collagen up-regulation of lysyl oxidase were focused on a potential role for 
collagen-integrin axis. We globally inhibited collagen-integrin binding and 
signaling with EDTA, and determined that the collagen-integrin axis has a limited 
role in collagen induction of lysyl oxidase in osteoblasts. 
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DDR2 was recently reported to cooperate with integrins a1 J31 and a2J31 
(collagen specific integrins expressed on osteoblasts) in its binding to collagen 
(Xu eta/., 2012). Therefore, the partial attenuation of lysyl oxidase induction by 
collagen observed in our integrin signaling inhibition studies on non-
differentiating primary mouse calvarial cells could be due to the potential 
interference of integrin signaling with DDR2-collagen bindings. The ablation of 
lysyl oxidase induction by collagen in DDR2 knockdown cells supports this 
hypothesis. However, the inhibition of integrin signaling by EDTA in rat primary 
osteoblasts did not change the levels of lysyl oxidase induction by collagen. 
These studies collectively suggest that integrin receptors role in the DDR2-
mediate up-regulation of lysyl oxidase by collagen varies between species and 
might be under the influence of the stage of differentiation in osteoblasts. 
Type I Collagen-specific a1 integrin-ablations in mice manifested as no 
overt phenotype or anatomical abnormality (Gardner eta/., 1996) although bone 
fracture healing in these mice was impaired (Ekholm et a/., 2002). Homozygous 
mice deficient for collagen-specific a 1 OJ31 integrin showed post-birth growth plate 
defects with no morphological skeletal deformities (Bengtsson et a/., 2005). 
lntegrin a2 deletion in mice revealed no striking anatomical phenotype 
(Biumbach eta/., 2012; Holtkotter eta/., 2002). In a recent study, mice ablated in 
a2J31-, a11 J31-, or both a2J31-a11 J31-integrins were born with no bone phenotype; 
however, long bone post-natal growth were reduced in mice lacking a11 J31- and 
a2J31-a11 J31-integrins. The authors demonstrated that a proportional dwarfism in 
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these mice is a consequence of insufficient systemic IGF-1 levels, and neither 
osteoblast dysfunction nor growth plate alterations contributed to this phenotype 
(Biumbach eta/., 2012). 
Taken together, collagen-activation of DDR2 appears to regulate activities 
of bone cells which directly synthesize bone extracellular matrix, and collagen-
integrin axis activation can be considered to cooperatively regulate bone growth 
and development (Biumbach eta/., 2012). 
5.1.5. AGE/RAGE Axis Does Not Regulate Lysyl Oxidase in Osteoblasts 
We have previously shown that the receptor for advanced glycation end 
products (RAGE) is expressed by osteoblasts in-vitro and in-vivo and that a 
RAGE ligand interferes with calvarial bone healing (Santana eta/., 2003). 
RAGE signaling activation has been linked to diabetic complications 
(Nawroth et a/., 2005), neurodegenerative disorders (Lue et a/., 2005), and 
inflammatory conditions (Bierhaus eta/., 2005). RAGE is a receptor with multiple 
ligands. The activation of AGE-RAGE signaling in human trabecular bone 
osteoblasts attenuates the levels of type I collagen and alkaline phosphatase 
protein levels, and also disrupts the mineralization in these cells (Sanguineti et 
a/., 2008). Here we found that despite the adverse effects of AGE-RAGE axis 
activation in diabetic bone complications, AGE-RAGE axis activation does not 
regulate lysyl oxidase protein levels in osteoblasts. 
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5.1.6. The Adverse Effects of Accumulated Glycated Collagen in Diabetic 
Bone 
In summary, combined with the current study, an understanding emerges 
that AGE-modification of collagen inhibits binding to integrins (McCarthy et a/., 
2004) and DDR2. As explained earlier in section 5.1.2, DDR2 is required for 
bone development and it is likely that the collagen-DDR2 signaling plays an 
important role in bone development. Take together, glycated collagen fails to 
bind and activate DDR2 signaling, while glycated collagen activates RAGE axis 
(Aiikhani et a/., 2007). Each of these two events independently contributes to 
bone complications seen in diabetes. 
5.2. In-Vivo Studies 
5.2.1. Diabetes Up-Regulates Lysyl Oxidase in Calvarial Bone Healing 
Tissues 
Our laboratory previously reported reduced intramembranous calvarial 
bone healing in STZ-induced diabetic mice. Insulin rescued the impaired bone 
healing in this model and the local delivery of CML-mouse serum albumin (CML-
MSA) independent of diabetes prompts abnormal calvarial bone healing 
(Santana eta/., 2003). Moreover, RAGE was detected in calvarial bone healing 
tissues in diabetic mice. Therefore, we reasoned that diabetes-induced 
accumulation of AGEs, such as CML-collagen, stimulates AGE/RAGE signaling, 
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which dysregulates genes like lysyl oxidase. Dysregulation of genes in response 
to AGE-RAGE signaling was shown to contribute in diabetes complications (Yan 
eta/., 201 0). 
In our recent studies aiming to determine the mechanisms of impaired 
intramembranous bone healing in diabetes, we initially hypothesized that the 
activation of AGE-RAGE axis, as explained above, down-regulates lysyl oxidase, 
which interferes with bone extracellular matrix maturation and thereby bone 
development. The evidence indicating reduced levels of lysyl oxidase enzyme-
dependent collagen cross-links in diabetic bones supported this hypothesis. 
In contrast to our initial hypothesis, lysyl oxidase mRNA and enzyme 
activity levels were up-regulated under diabetic conditions. Hence, the next 
series of experiments concentrated on histological analysis of calvarial bone 
healing under diabetic conditions to understand the up-regulation of lysyl oxidase 
in healing bone tissues as a function of diabetes. 
5.2.2. Excess of Non-Mineralized Fibrotic Matrix Disrupts Intramembranous 
Bone Healing in Diabetes 
Bone healing is broadly divided into endochondrial and intramembranous 
ossification (bone-formation). In intramembranous ossification, progenitor 
mesenchymal cells differentiate into osteoblasts (bone-forming cells) that deposit 
the bone matrix, which is mineralized in time. In endochondrial ossification, the 
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progenitor mesenchymal cells differentiate into chondrocytes (cartilage-forming 
cells). Chondrocytes form a transient cartilage tissue, which is replaced by the 
bone matrix and is mineralized to form mature bone. The intramembranous bone 
ossification lacks the transient cartilage tissue formation (Zuscik eta/., 2009). 
The mechanism(s) behind impaired bone healing in diabetes has not been 
fully understood. Two mechanisms have been proposed to explain bone healing 
disorders in diabetes: (i) reduced chondrogenesis in diabetic bone healing, (ii) 
diminished osteoblast proliferation and differentiation during bone healing in 
diabetes. The former hypothesis mainly applies to endochondrial bone formation 
and not intramembranous bone formation. 
5.2.2.1. Enhanced cartilage removal as a function of diabetes in 
endochondrial ossification 
Reduced chondrogenesis in early stages of bone healing was proposed 
as one the mechanisms of impaired bone healing in diabetes. Ogasawara et a/. 
reported lower levels of type II and X collagens in diabetic bone fracture healing 
tissue, which suggests reduced cartilage formation (Ogasawara et a/., 2008). In 
addition, studies on diabetic mouse fracture bone healing showed that the newly 
formed bone callus is reduced in diabetic mice. Further, the authors reported 
higher osteoclast numbers at day 16 of healing, and higher levels of cytokines 
and proteases, such as TNF-a and ADAMTS 4 and 5. Therefore, they suggested 
that the enhanced removal of cartilage as a function of diabetes results in a 
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reduced scaffold for new bone formation, which explains reduced callus bone 
formation in diabetes (Kayal et a/., 2010). Further studies to determine the 
mechanisms of enhanced cartilage removal in diabetes suggested that elevated 
levels TNF-a and ROS in diabetes induce chondrocytes apoptosis via up-
regulation of Forkhead Box protein 01 (FOX01) (Siqueira eta/., 2010). Note that 
this mechanism mainly applies to endochondrial ossification and most likely does 
not occur in intramembranous bone formation. 
5.2.2.2. Diminished Osteoblast Proliferation and Differentiation Under 
Diabetic Conditions 
Several in-vitro studies suggested diminished osteoblast function under 
diabetic conditions. 
The Manolagas group reported on the up-regulation of FOXO signaling 
and down regulation of Wnt signaling in aging mouse bones. Further, the up-
regulated FOX03a in H202-stimulated uncommitted mesenchymal cells was 
shown to compete with Wnt signaling. This competition inhibits the Wnt-
stimulated differentiation of uncommitted mesenchymal cells into osteoblasts. 
The authors suggested that elevated levels of ROS in diabetes antagonize Wnt 
signaling and inhibits osteoblast differentiation (Almeida eta/., 2007). 
Ogawa et a/. reported no significant mineralization changes in 
differentiated MC3T3 osteoblasts under AGE-stimulation. The authors showed 
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the up-regulation of RAGE, a class of receptors binding to AGEs, in the early 
stage of differentiation in cells incubated with 22mM glucose and in the later 
stage of differentiation when cells were incubated with AGE-BSA. The levels of 
Osteocalcin mRNA on differentiation day 21 and 14 was down-regulated in cells 
differentiated in the presence of both 22 mM glucose and 300 IJg/ml AGE-BSA. 
The authors collectively suggested that the combination of AGEs and glucose 
does inhibit osteoblast differentiation most likely via activation of AGE-RAGE 
signaling (Ogawa eta/., 2007). 
Studies on bone marrow stromal cells (BMSCs) and primary calvarial 
osteoblasts showed that a non-toxic dose of reactive oxygen species inhibits the 
phosphorylation of Runt-related transcription factor 2 (RUNX2) and synthesis of 
type I collagen in BMSCs. RUNX2 is the master transcription factor regulating the 
genes required for osteoblast differentiation (Komori et a/., 1997; Otto et a/., 
1997; Rodan eta/., 1997). Additionally, it was reported that the inhibition of ERK-
dependent NF-KB rescued the inhibition of phospho-RUNX2 by H202 in both 
BMSCs and calvarial primary osteoblasts. The authors collectively suggested 
that reactive oxygen species, which is elevated in diabetes, interfere with 
osteoblast differentiation via an ERK-dependent pathway through the regulation 
of RUNX2, an important transcription factor in osteoblast differentiation (Bai et 
a/., 2004). 
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All these in-vitro studies together indicate that diabetes leads to 
diminished osteoblast differentiation. However, it is unclear whether diabetes-
induced osteoblast dysfunction causes impaired bone healing in diabetes or it 
contributes to the pool of complications in diabetes, which lead to impaired bone 
healing in diabetes. For example, an excess or insufficient angiogenesis in 
different tissues has been reported in diabetes (Martin et a/., 2003) . 
Angiogenesis is the initial stage of bone healing thus potential diabetes-
associated complications at this stage would interfere with the later stages of 
bone healing and eventually with the bone healing in general. 
5.2.2.3. Excess of Non-Mineralized Fibrotic Matrix Interference with Bone 
Healing in Diabetes 
Our group previously reported an AGE-dependent mechanism for 
diminished diabetic intramembranous bone healing (Santana et a/., 2003). Our 
new studies on calvarial intramembranous bone healing in diabetic mice reported 
on the excess formation of a non-mineralized fibrotic matrix in diabetic bone 
healing , which is potentially due to unresolved hematomas. Accumulated 
platelets, as byproducts of unresolved hematomas, could result in elevated levels 
of TGF-~, which is known to up-regulate lysyl oxidase (Soak et a/., 1994; Feres-
Filho eta/., 1995). TGF-~ inhibits later stages of bone formation (Tang eta/., 
2013). We also showed the up-regulation of lysyl oxidase mRNA and enzyme 
activity in diabetic bone healing tissues. Up-regulation of lysyl oxidase is a 
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hallmark of fibrosis (Kagan, 2000). Taken together, we reason that the 
unresolved hematomas, a rich source of cytokines and growth factors, tip the 
balance of cell proliferation in the healing tissue to fibroblasts proliferation at the 
expense of osteoblasts, leading to formation of an excess non-mineralized 
matrix. Collectively, these events favor the formation of a fibrotic matrix in the 
healing bone tissue that disrupts normal course of bone healing. Further studies 
are required to further examine this hypothesis. 
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6. Conclusion 
In conclusion, we have shown that collagen stimulates osteoblasts to 
increase lysyl oxidase levels, thereby maintaining its steady state normal 
physiological level. Our data also indicate that collagen activation of DDR2, 
potentially with integrin receptors cooperation, up-regulates lysyl oxidase in 
osteoblasts. 
We found that elevated glycation of collagen, which occurs in aging and in 
diabetes, interferes with collagen to DDR2 binding and activation, hence failing to 
maintain lysyl oxidase levels made by osteoblasts. Furthermore, the activation of 
AGE/RAGE signaling by glycated proteins including collagen does not regulate 
lysyl oxidase in diabetes. Collagen glycation under diabetic conditions disrupts 
collagen-DDR2 signaling activation and consequently the induction of lysyl 
oxidase by collagen (Figure 27). This failure in the regulation of lysyl oxidase due 
to glycation of collagen in diabetes results in reduced levels of collagen cross-
links and hence diminished bone strength in diabetes. Additionally, the 
accumulation of glycated collagen in aging bones and its failure to regulate lysyl 
oxidases in osteoblasts may partly explain bone fragility in older individuals. 
Our intramembranous bone healing model in diabetic mice suggested 
formation of an excess non-mineralized matrix under diabetic conditions, which 
can explain abnormal intramembranous bone healing in diabetes. 
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Collectively, our findings provided novel insights into the multiple 
mechanisms by which diabetes affects bone development and healing and may 
provide new opportunities for addressing diabetic osteopenia. 
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Figure 27. Schematic of Proposed Model on The Regulation of Lysl Oxidase by 
Collagen and Glycated Collagen in Osteoblasts 
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Figure 27. Schematic of Proposed Model on The Regulation of Lysl Oxidase by 
Collagen and Glycated Collagen in Osteoblasts 
The schematic shows the potential mechanisms for lysyl oxidase 
regulation by collagen and glycated collagen in osteoblasts. 
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